Cardiac fibrosis
Open accessThe DOI matches its Crossref record; 612 of the 615 references it cites were found in a registry or an index.
Abstract
Myocardial fibrosis, the expansion of the cardiac interstitium through deposition of extracellular matrix proteins, is a common pathophysiologic companion of many different myocardial conditions. Fibrosis may reflect activation of reparative or maladaptive processes. Activated fibroblasts and myofibroblasts are the central cellular effectors in cardiac fibrosis, serving as the main source of matrix proteins. Immune cells, vascular cells and cardiomyocytes may also acquire a fibrogenic phenotype under conditions of stress, activating fibroblast populations. Fibrogenic growth factors (such as transforming growth factor-β and platelet-derived growth factors), cytokines [including tumour necrosis factor-α, interleukin (IL)-1, IL-6, IL-10, and IL-4], and neurohumoral pathways trigger fibrogenic signalling cascades through binding to surface receptors, and activation of downstream signalling cascades. In addition, matricellular macromolecules are deposited in the remodelling myocardium and regulate matrix assembly, while modulating signal transduction cascades and protease or growth factor activity. Cardiac fibroblasts can also sense mechanical stress through mechanosensitive receptors, ion channels and integrins, activating intracellular fibrogenic cascades that contribute to fibrosis in response to pressure overload. Although subpopulations of fibroblast-like cells may exert important protective actions in both reparative and interstitial/perivascular fibrosis, ultimately fibrotic changes perturb systolic and diastolic function, and may play an important role in the pathogenesis of arrhythmias. This review article discusses the molecular mechanisms involved in the pathogenesis of cardiac fibrosis in various myocardial diseases, including myocardial infarction, heart failure with reduced or preserved ejection fraction, genetic cardiomyopathies, and diabetic heart disease. Development of fibrosis-targeting therapies for patients with myocardial diseases will require not only understanding of the functional pluralism of cardiac fibroblasts and dissection of the molecular basis for fibrotic remodelling, but also appreciation of the pathophysiologic heterogeneity of fibrosis-associated myocardial disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inflammation and tissue fibrosis co-exist and are causally linked to organ dysfunction1,2.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [2]
In the citing paper
“Among stromal cell types, fibroblasts are of particular interest given their role in tissue fibrosis, arrhythmias, and heart failure 16,29,30 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [30]
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495 · cited 1×
“Fibrosis is an important cause of organ dysfunction in many different diseases, including interstitial lung diseases, liver cirrhosis, progressive systemic sclerosis, and diabetic nephropathy.(1)”
BackgroundMyofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Obesity and the risk of heart failure
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., Kannel, W. B., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020245 · Cited by 3,093
Ignotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis
Prabhu, S. D., & Frangogiannis, N. G. (2016) · Circulation Research · doi:10.1161/circresaha.116.303577 · Cited by 2,224
Self-citationEndothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222 · cited 2×
“The antifibrotic effects were attributed to blockade of TGF-b signalling and were associated with attenuated endothelial to mesenchymal transition.(22,247) Moreover, gain-of-function studies have”
BackgroundHinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Cited by
Items 401–500 of 1,000
Fibroblasts and platelets: a face-to-face dialogue at the heart of cardiac fibrosis
Dufeys, C., Bodart, J., Bertrand, L., Beauloye, C., & Horman, S. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00559.2023 · Cited by 13
Wang, Y., Duan, X., Zhu, L., Xu, J., Zhou, D., Yang, W., Jiang, M., Zhang, H., Sirajuddin, A., Arai, A. E., et al. (2025) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.240125 · Cited by 14
Role of circadian transcription factor REV-ERB in cardiovascular diseases: a review
Wang, C., Yang, J., Yuan, J., Wang, X., Li, Q., Ren, C., Zhi, X., Lv, X., Liu, K., Zhao, X., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1516279 · Cited by 15
Cremer, S., von Scheidt, M., Kirschbaum, K., Tombor, L., Mas‐Peiró, S., Abplanalp, W. T., Rasper, T., Ware, A. P., Schuff, A., Berkowitsch, A., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3778 · Cited by 13
“1 6 As diffuse cardiac fibrosis represents the common denominator of progression of all forms of chronic heart failure, 33 we hypothesized that the presence of LOY might associate with worse survival in patients with established chronic heart failure.”
Cell type specificity of Hippo-YAP signaling in cardiac development and disease
Guan, J., & Re, D. P. D. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.08.003 · Cited by 13
“The role of fibrosis and inflammation in heart disease is particularly important, as they both contribute to excessive ECM accumulation that results in impaired cardiac contraction and relaxation, increased susceptibility to arrhythmias, and impaired cardiac function [15-17].”
The Scientific Rationale for the Introduction of Renalase in the Concept of Cardiac Fibrosis
Stojanović, D. R., Mitić, V., Stojanović, M., Milenković, J., Ignjatović, A., & Milojković, M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.845878 · Cited by 15
“Despite its prevalence, there is a scarcity of effective approaches for the suppression or reversion of cardiac fibrosis (8), most likely because cardiac fibrosis does not represent a single disease, but rather a general inappropriate response to trauma (1).”
BackgroundInfluentialDefining cardiac fibrosis complexity and regulation towards therapeutic development
Claridge, B., Drack, A., Pinto, A. R., & Greening, D. W. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.163 · Cited by 16
Mareş, R. G., Sabău, A.-H., Cocuz, I. G., Tomuţ, M. E., Szabó, I. A., Cozac-Szőke, A. R., Tinca, A. C., Jakobsson, G., Cotoi, O. S., & Şchiopu, A. (2023) · Romanian Journal of Morphology and Embryology · doi:10.47162/rjme.64.2.04 · Cited by 13
An Overview of Diabetic Cardiomyopathy
Quaiyoom, A., & Kumar, R. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998255538231001122639 · Cited by 14
lncRNA HOTAIR and Cardiovascular diseases
Taghvimi, S., Fard, E. S., Khatami, S. H., z.m, S. Z., Taheri‐Anganeh, M., Movahedpour, A., & Ghasemi, H. (2024) · Functional & Integrative Genomics · doi:10.1007/s10142-024-01444-6 · Cited by 14
“However, persistent or severe fibrotic reactions can lead to excessive ECM deposition, resulting in myocardial hardness, poor tissue compliance, and worsening of cardiac dysfunction (Frangogiannis 2020).”
Zhou, Z., Ma, D., Zhou, Y., Zhang, K., Liu, Y., Wang, Z., & Wang, Y. (2023) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2023/6018375 · Cited by 12
Onion quercetin inhibits vascular endothelial cell dysfunction and prevents hypertension
Yamagata, K. (2023) · European Food Research and Technology · doi:10.1007/s00217-023-04368-w · Cited by 12
“Cardiac fibroblasts play an important role in myocardial remodeling and myocardial fibrosis, and pathological changes involving these cells can ultimately lead to myocardial infarction [98].”
CXCL4:NLRP3-mediated pyroptosis product that regulates cardiac fibrosis
Wei, J., Peng, M. Y., Wang, S. N., Tan, J. J., & Lu, H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112096 · Cited by 12
The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on the ‘Forgotten’ Right Ventricle
Qu, L., Duan, X., & Chen, H. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15103 · Cited by 12
Shen, L., Fu, S., Li, W., Yu, K., Ran, Y., Shi, G., Tan, H., Huang, F., Li, Q., Li, Y., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.159980 · Cited by 12
Wu, Y., Li, M., Zhan, S., Li, M., Huang, J., Chen, X., Chen, L., Gao, X., Chen, H., Chen, H., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06244-5 · Cited by 12
The Role of Signalling Pathways in Myocardial Fibrosis in Hypertrophic Cardiomyopathy
Skórka, P., Piotrowski, J., Bakinowska, E., Kiełbowski, K., & Pawlik, A. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm27152 · Cited by 12
Leblanc, F., Yiu, C. H. K., Moreira, L. M., Johnston, A. M., Mehta, N., Kourliouros, A., Sayeed, R. A., Nattel, S., Reilly, S. N., & Lettre, G. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00626-0 · Cited by 12
“In addition to FB activation, ECM accumulation is a major component of fibrosis 19 , which is characterized by increased production of key ECM components, such as type I collagen ( COL1A1 ), type III collagen ( COL3A1 ), fibronectin ( FN1 ) and periostin ( POSTN ).”
Bai, R., Wu, L., Wang, Y., Guo, C., She, G., Pang, Z., Li, J.-J., Zhao, X.-Y., Han, M.-Z., Hai, X.-X., et al. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2811-x · Cited by 14
“…of the cellular responses to cardiac stress is how quiescent fibroblasts are activated and differentiate into activated subtypes (e.g., myofibroblasts) with distinct profibrotic gene profiles (Frangogiannis, 2021), which contribute to the cellular and molecular changes in myocardial fibrosis.”
Decoding mechanosensitive genes in cardiac fibroblasts via 3D hydrogel models of fibrosis
Chen, H., Chen, Y., Yang, J., Yang, P. F., Cheng, H., & Guo, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-16708-9 · Cited by 13
Tang, H. D., Zhang, L., Deng, C., Li, Y., Ren, G., Sun, Z., Chang, L., Xu, M., Xiao, D., & Zhang, H. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s534720 · Cited by 13
Hopes and Hurdles of Employing Mesenchymal Stromal Cells in the Treatment of Cardiac Fibrosis
Neuber, S., Emmert, M. Y., & Nazari‐Shafti, T. Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313000 · Cited by 13
“Cardiac fibrosis accompanies most cardiac pathological conditions and is a critical contributor to the progression of heart failure [1].”
BackgroundKocurková, A., Nešporová, K., Sandanusova, M., Kerberova, M., Lehká, K., Velebný, V., Kubala, L., & Ambrožová, G. (2021) · Biomolecules · doi:10.3390/biom12010045 · Cited by 15
“However, it seems that the production of HA in fibrotic conditions is not only a passive consequence of cell activation but HA can also affect processes related to the TGFβ signaling pathway, as was observed for example in cardiac fibroblasts [89].”
BackgroundTargeting cholesteryl ester accumulation in the heart improves cardiac insulin response
Dato, V. A., Amaro, A. B., García, E., Claudi, L., Lhoëst, M. T. L. C., Iborra, A., Escolá‐Gil, J. C., Palmero, M. J. G., Samouillan, V., Enrich, C., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113270 · Cited by 12
The complicated lives of GPCRs in cardiac fibroblasts
Mazarura, G. R., Dallagnol, J. C. C., Chatenet, D., Allen, B. G., & Hébert, T. E. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00120.2022 · Cited by 13
Al-U'datt, D. G. F., Tranchant, C. C., Alu'datt, M. H., Abusara, S., Al‐Dwairi, A., Alqudah, M., Al-Shboul, O. A., Hiram, R., Altuntaş, Y., Jaradat, S. A., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121564 · Cited by 13
Panagiotides, N. G., Poledniczek, M., Andreas, M., Hülsmann, M., Kocher, A. A., Kopp, C. W., Piechota-Polańczyk, A., Weidenhammer, A., Pávó, N., & Wadowski, P. P. (2024) · Viruses · doi:10.3390/v16010121 · Cited by 13
Stephan, J., Knerr, T., Gu, Z., Li, H., Brittian, K. R., Dassanayaka, S., Singhal, R. A., Nong, Y., Jones, S. P., & Wysoczynski, M. (2025) · The FASEB Journal · doi:10.1096/fj.202401654r · Cited by 12
“Because CHI3L1 promotes non-resolving inflammation in vivo, and prolonged inflammation antagonizes scar formation post-MI, 2,4,5 we next tested the role of CHI3L1 in ventricular remodeling and function after MI.”
Loss of BTK ameliorates the pathological cardiac fibrosis and dysfunction
Wang, B., Tan, Y., Zhou, W., Yang, J., Jiang, Y., Liu, X., & Zhan, Z. (2022) · Matrix Biology · doi:10.1016/j.matbio.2022.08.010 · Cited by 12
Exosomal miR‑152‑5p/ARHGAP6/ROCK axis regulates apoptosis and fibrosis in cardiomyocytes
Chen, S., Huang, Y., Liu, R., Lin, Z., Huang, B., Ai, W., He, J., Gao, Y., & Xie, P. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11864 · Cited by 12
Targeting galectin-3 in myocardial infarction: a unique opportunity for biomarker-guided therapy
Frangogiannis, N. G. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad156 · Cited by 12
Self-citationSet7 deletion attenuates isoproterenol-induced cardiac fibrosis and delays cardiac dysfunction
Lunardon, G., Silva, T. D. O., Lino, C. A., Lu, Y. W., Miranda, J. B., Asprino, P. F., Silva, A. D. A., Nepomuceno, G. L. J. T., Irigoyen, M. C., Carneiro‐Ramos, M. S., et al. (2022) · Clinical Science · doi:10.1042/cs20220466 · Cited by 11
Trends in worldwide research on cardiac fibrosis over the period 1989–2022: a bibliometric study
Mao, Y., Fu, Q., Feng, S., Zhang, W., Zhong, Z., Zhou, Y., & Yang, C. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1182606 · Cited by 11
Novel Biomarkers and Advanced Cardiac Imaging in Aortic Stenosis: Old and New
Drăgan, A., & Mateescu, A. D. (2023) · Biomolecules · doi:10.3390/biom13111661 · Cited by 13
Delaunay, M., Paterek, A., Gautschi, I., Scherler, G., & Diviani, D. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119674 · Cited by 12
Mechanical stimulation of induced pluripotent stem cell derived cardiac fibroblasts
Bekedam, F. T., Smal, R., Smit, M. C., Aman, J., Noordegraaf, A. V., Bogaard, H. J., Goumans, M., de Man, F. S., & Valldeperas, A. L. (2024) · Scientific Reports · doi:10.1038/s41598-024-60102-w · Cited by 11
“CFs are the main contributors of cardiac fibrosis development 3 .”
BackgroundYang, S., Pei, L., Huang, Z., Zhong, Y., Li, J., Hong, Y., Long, H., Chen, X., Zhou, C., Zheng, G., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00856-1 · Cited by 11
Khalil, N. N., Rexius‐Hall, M. L., Gupta, D., McCarthy, L., Verma, R., Kellogg, A. C., Takamoto, K., Xu, M., Nejatpoor, T., Parker, S. J., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401478 · Cited by 11
SGLT2 inhibitors: how do they affect the cardiac cells
Erdoğan, B. R., & Arioglu‐Inan, E. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05084-z · Cited by 11
“In addition, cardiac fibrosis itself contributes to systolic and diastolic dysfunction in many heart diseases [16, 17], therefore, reducing fibrosis is a therapeutic strategy in cardiac diseases [18].”
Sun, M., Liu, C., Gao, K., Xu, X., Chen, K., Qiu, L., & Wang, X. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310897 · Cited by 11
Li, X., Li, D., Liu, S., Wang, Y., Fan, X., Yan, Z., Tan, S., Zhuang, P., & Zhang, Y. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157529 · Cited by 11
Coeyman, S. J., Richardson, W. J., & Bradshaw, A. D. (2022) · Current Opinion in Physiology · doi:10.1016/j.cophys.2022.100560 · Cited by 15
Yuan, P., Liu, J., Xiong, S., Yang, L., Guan, J., Dong, G., & Shi, D. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116558 · Cited by 11
Wei, X., Lv, Y., Yang, C., Gao, R., Zou, S., & Xu, Y. (2023) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13783 · Cited by 11
“Fibroblasts and myofibroblasts produce fibres and extracellular matrix to replace the damaged tissue.(18) Therefore, we investigated whether bufalin could alleviate MI-induced fibrosis.”
BackgroundLuu, R. J., Hoefler, B. C., Gard, A. L., Ritenour, C. R., Rogers, M. T., Kim, E. S., Coppeta, J. R., Cain, B. P., Isenberg, B. C., Azizgolshani, H., et al. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1160851 · Cited by 12
“Fibrosis can occur in various tissues such as the heart (Frangogiannis, 2020), lung (Martinez et al., 2017), liver (Hernandez-Gea and Friedman, 2011), and kidney (Duf fi eld, 2014), leading to organ failure, the need for organ transplant, or, if left untreated, death.”
Delgado‐Arija, M., Genovés, P., Pérez-Carrillo, L., González-Torrent, I., Giménez-Escamilla, I., Martínez‐Dolz, L., Portolés, M., Tarazón, E., & Roselló‐Lletí, E. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04900-w · Cited by 12
“Unfortunately, there is no specific therapy to reverse this myocardial fibrosis, and treatments only improve the clinical symptoms of these patients [5, 6].”
BackgroundShen, J., Liang, J., Rejiepu, M., Ma, Z., Zhao, J., Li, J., Zhang, L., Yuan, P., Wang, J., & Tang, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-55613-5 · Cited by 11
Madsen, P. L., Sejersen, C., Nyberg, M., Sørensen, M. H., Hellsten, Y., Gæde, P., & Bojer, A. S. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1294369 · Cited by 11
“DM is associated not only with more narrow coronary arteries, but also with stiffening of the peripheral conductance arteries with notably smaller diameters (Frangogiannis, 2021).”
BackgroundRNA-mediated epigenetic regulation in exercised heart: Mechanisms and opportunities for intervention
Wang, L., Wan, W., Zhang, S., Keswani, T., Li, G., & Xiao, J. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101274 · Cited by 11
Panagopoulos, I., Andersen, K., Gorunova, L., & Lobmaier, I. V. K. (2024) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20444 · Cited by 11
Yang, N., Hou, Y.-B., Cui, T.-H., Yu, J., He, S., & Zhu, H. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s463477 · Cited by 11
Miglustat ameliorates isoproterenol-induced cardiac fibrosis via targeting UGCG
Liu, J., Li, W., Jiao, R., Liu, Z., Zhang, T., Chai, D., Meng, L., Yang, Z., Liu, Y., Wu, H., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01093-w · Cited by 12
Li, Q., Ren, C., Jiang, B., Wang, X., Wang, C., Zhi, X., Li, L., Guo, X., Zhao, X., & Li, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1554696 · Cited by 11
“Excessive activation can cause the accumulation and remodeling of the ECM, impairing cardiac function and potentially leading to heart failure (Frangogiannis, 2021).”
Targeting GPCRs to treat cardiac fibrosis
Zhang, H., Ren, L., & Shivnaraine, R. V. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1011176 · Cited by 14
“This accumulation accompanies most cardiac pathologic conditions, such as myocardial stiffness and diastolic dysfunction, and the extent of cardiac fibrosis is a predictor of adverse outcomes (3).”
BackgroundLiu, L., Sun, K., Luo, Y., Wang, B., Yang, Y., Chen, L., Zheng, S., Wu, T., & Xiao, P. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121470 · Cited by 11
Zhang, Y., Steinmetz‐Späh, J., Idborg, H., Zhu, L., Li, H., Rao, H., Chen, Z., Guo, Z., Hu, L., Xu, C., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16061 · Cited by 11
Abecasis, J., Cortez‐Dias, N., Pinto, D. G., Lopes, P. M., Madeira, M., Ramos, S., Gil, V. M., Cardim, N. M., & Félix, A. (2023) · Cardiovascular Pathology · doi:10.1016/j.carpath.2023.107541 · Cited by 10
Yang, Y., Yang, H., Kiskin, F. N., & Zhang, J. Z. (2024) · Medical Review · doi:10.1515/mr-2023-0059 · Cited by 12
Kramer, T., Ventovuori, V., Heinonen, A. O., Parkkari, J. P., Korhonen, M. T., Rovio, A. T., Hoenemann, J.-N., Möstl, S., Sies, W., Kaiser‐Stolz, C., et al. (2024) · BMJ Open Sport & Exercise Medicine · doi:10.1136/bmjsem-2024-001988 · Cited by 11
Samani, S. L., Barlow, S. C., Freeburg, L., Catherwood, G., Churillo, A. M., Jones, T. L., Altomare, D., Ji, H., Shtutman, M. S., Zile, M. R., et al. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00551.2023 · Cited by 10
miR-210 overexpression increases pressure overload-induced cardiac fibrosis
Zaccagnini, G., Baci, D., Tastsoglou, S., Cozza, I. C., Madè, A., Voellenkle, C., Nicoletti, M., Ruatti, C., Longo, M., Perani, L., et al. (2025) · Non-coding RNA Research · doi:10.1016/j.ncrna.2025.01.009 · Cited by 10
Myocardial Characterization on CT: Late Iodine Enhancement and Extracellular Volume
Bartoli, A., Gnasso, C., Palmisano, A., Bettinelli, A., Vignale, D., & Esposito, A. (2025) · Echocardiography · doi:10.1111/echo.70108 · Cited by 10
Martin, E. M., Chang, J., González, A., & Genovese, F. (2025) · Matrix Biology · doi:10.1016/j.matbio.2025.03.001 · Cited by 10
Santos, M. C., Birkenfeld, L., Pham, T., Maier, S., Paulus, K., Ullemeyer, L., Knauer, A., Kabagema‐Bilan, C., Längst, N., Roslan, A., et al. (2025) · Clinical Science · doi:10.1042/cs20241204 · Cited by 10
AEBP1 or ACLP, which is the key factor in inflammation and fibrosis?
Runtian, Z., Wenqiang, H., Zimeng, S., Tianyu, W., & Jingquan, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143554 · Cited by 12
A secretome atlas of cardiac fibroblasts from healthy and infarcted mouse hearts
Bahr, J., Poschmann, G., Jungmann, A., Busch, M., Ding, Z., Vogt, J., Zalfen, R., Steinhausen, J., Martínez, A. A. E., Wachtmeister, T., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08083-y · Cited by 10
Popazova, O., Belenichev, I. F., Bukhtiyarova, N. V., Ryzhenko, V. P., Gorchakova, N., Oksenych, V., & Kamyshnyi, O. (2025) · Antioxidants · doi:10.3390/antiox14060743 · Cited by 13
Ren, W., Xi, Y., Ma, Y., Duan, X., Wang, T., Yu, M., Qin, S., Gong, D., & Tian, Z. (2025) · The FASEB Journal · doi:10.1096/fj.202402897rr · Cited by 10
Heart failure: mechanistic insights and precision therapeutic strategies
Zhang, F., Zhang, X., Jian, J., Zeng, X., Zheng, C., Zhang, Y., & Gao, J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1696793 · Cited by 12
Melanocortin therapies to resolve fibroblast-mediated diseases
Khodeneva, N., Sugimoto, M. A., Davan-Wetton, C. S. A., & Montero‐Melendez, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1084394 · Cited by 12
“Fibrosis can manifest in many organ systems, like skin fibrosis including keloids and hypertrophic scars (51); pulmonary fibrosis, caused by exposure to pollutants like asbestos, chemotherapy agents or bacterial and viral infections (52–54); liver fibrosis, associated with alcoholism, fatty liver disease or viral infe…”
BackgroundThe role of myeloid-derived immunosuppressive cells in cardiovascular disease
Li, Q., Mei, A., Qian, H., Min, X., Yang, H., Zhong, J., Li, C., Xu, H. Y., & Chen, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109955 · Cited by 10
SOCS3 Silencing Promotes Activation of Vocal Fold Fibroblasts via JAK2/STAT3 Signaling Pathway
Li, X., Hu, R., Wang, H., & Xu, W. L. (2023) · Inflammation · doi:10.1007/s10753-023-01810-9 · Cited by 11
“Neurohumoral pathways trigger fibrogenic signaling pathways and activate downstream signaling cascades [3, 4].”
BackgroundMyocardial fibrosis in rheumatic heart disease: emerging concepts and clinical implications
Putra, T. M. H., Rodríguez-Fernández, R., Widodo, W. A., Elfiana, M., Laksono, S., Nguyen, Q. N., Tan, J. W. C., & Narula, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1230894 · Cited by 13
“Interventions at any point within the continuum may modify disease progression and prevent further remodeling and fibrosis (72).”
BackgroundPerez-Estenaga, I., Chevalier, M. T., Peña, E., Abizanda, G., Alsharabasy, A. M., Larequi, E., Cilla, M., Pérez, M. M., Gurtubay, J., Castro, M., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c04245 · Cited by 10
Personalized biomechanical insights in atrial fibrillation: opportunities & challenges
Telle, Å., Bargellini, C., Chahine, Y., del Álamo, J. C., AKOUM, N. W., & Boyle, P. M. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2273896 · Cited by 10
Chen, Y.-W., Cheng, P., Yin, Y., Cai, H., Chen, J.-Z., Feng, M., Guo, W., Zhao, P., Zhang, C., Shan, X., et al. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149360 · Cited by 12
COX6A2 deficiency leads to cardiac remodeling in human pluripotent stem cell-derived cardiomyocytes
Jiang, M., Song, Y., Chen, X., Lü, W., Zhu, M., Wei, M., Lan, F., Cui, M., & Bai, Y. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03596-x · Cited by 11
“It affects the function of cardiomyocytes, and type I collagen α1 chain (COL1A1) and type IV collagen α1 chain (COL4A1) play an important role in inhibiting the occurrence and development of myocardial fibrosis [3].”
BackgroundThe role of TGF-β in cardiac fibrosis and heart failure: A review
Shah, G. B., & Prajapati, A. K. (2024) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2024.001 · Cited by 11
The Senescent Heart—“Age Doth Wither Its Infinite Variety”
Vijayakumar, A., Wang, M., & Kailasam, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073581 · Cited by 11
“On the other hand, enhanced expression of miR-22 during aging promotes fibroblast migration and senescence, at least in part via proteoglycan mimecan/osteoglycin, contributing to fibrogenesis [212]. miR 21, which is elevated in the aging heart, exerts pro-fibrotic effects on cardiac fibroblasts via…”
BackgroundDong, T., Huang, D., & Jin, Z. (2024) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-024-02692-0 · Cited by 10
“Similar to the results reported by Krishnamurthy P et al. [38], our findings revealed that IL-10 exhibited pro-fibrotic effects in CFs.”
BackgroundResultResearch Progress of Triptolide Against Fibrosis
Jiang, M., Xie, Y., Wang, P., Du, M., Wang, Y., & Yan, S. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s467929 · Cited by 10
“61 NF-κB pathway is a classic inflammatory pathway.”
BackgroundSulistomo, H. W., Aditya, M. R., Muhammad, A., & Rahma, O. A. (2024) · All Life · doi:10.1080/26895293.2024.2409835 · Cited by 11
Comella, F., Aragón‐Herrera, A., Pirozzi, C., Feijóo‐Bandín, S., Lama, A., Opallo, N., Melini, S., Piano, F. D., Gualillo, O., Meli, R., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123226 · Cited by 10
Diagnostic and Therapeutic Properties of Exosomes in Cardiac Fibrosis
Fan, J., Ren, M., & He, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.931082 · Cited by 10
“This leads to abnormalities in cardiac function and metabolism and is commonly seen at the end stages of several cardiovascular diseases (Pathak et al., 2005; Frangogiannis, 2019, 2021).”
BackgroundTian, Y., Gao, Z., Liu, W., Li, J., Jiang, X. M., & Xin, Y. (2022) · Antioxidants · doi:10.3390/antiox11122391 · Cited by 11
Li, W., Jin, Q., Zhang, L., He, S., Song, Y., Xu, L., Deng, C., Wang, L., Qin, X., & Xie, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030729 · Cited by 10
“Preventing fibrosis can effectively protect heart function [17].”
BackgroundZhang, S., Xie, H., Du, Y., Wang, B., Lan, B., & Wang, H. (2023) · General Physiology and Biophysics · doi:10.4149/gpb_2023018 · Cited by 9
Decoding the Impact of the Hippo Pathway on Different Cell Types in Heart Failure
Hu, C., Francisco, J. J., Re, D. P. D., & Sadoshima, J. (2024) · Circulation Journal · doi:10.1253/circj.cj-24-0171 · Cited by 9
Cao, M., Zhao, Q., Xia, H., Lyu, S., Luo, J., Fu, K., Chen, R., & Yuan, W. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116271 · Cited by 9
Ai, W., Casey, C. A., Mishra, P. K., Alnouti, Y., Daria, S., & Saraswathi, V. (2024) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15391 · Cited by 9
Wu, X., Lee, Y.-K., Lau, Y., Au, K., Tse, Y.-L., Ng, K., Wong, C., & Tse, H. (2024) · Pharmaceuticals · doi:10.3390/ph17081030 · Cited by 9
The Macrophage–Fibroblast Dipole in the Context of Cardiac Repair and Fibrosis
Psarras, S. (2024) · Biomolecules · doi:10.3390/biom14111403 · Cited by 9
Zhang, Z., Yan, Z., Yuan, T., Zhao, X., Wang, M., Liu, G., Gan, L., & Qin, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1549487 · Cited by 9
“…to investigate the mechanism behind the imbalanced collagen distribution caused by PD-1 inhibitor, we examined the in fl uence of PD-1 inhibitor on CFs, the primary cells responsible for the synthesis of extracellular matrix proteins (Burke et al., 2021; Frangogiannis, 2021; Liu et al., 2021).”
Automated prediction of fibroblast phenotypes using mathematical descriptors of cellular features
Khang, A., Barmore, A., Tseropoulos, G., Bera, K., Batan, D., & Anseth, K. S. (2025) · Nature Communications · doi:10.1038/s41467-025-58082-0 · Cited by 10
Dressed in Collagen: 2D and 3D Cardiac Fibrosis Models
Cardona-Timoner, M., Gomes, R. N., & Nascimento, D. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073038 · Cited by 9
SLC7A11 in Fibrosis: Molecular Mechanisms and Future Prospects
Chen, J., He, Y., Chen, R., Yang, Z., Luo, X., & Yang, F. (2025) · Aging and Disease · doi:10.14336/ad.2025.0106 · Cited by 11
Liu, B., Jin, Q., Sun, Y., Yang, Z. M., Meng, P., Zhang, X., Chen, Q., Gan, P., Zhao, T., He, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1563362 · Cited by 11
EZH2 in non-cancerous diseases: expanding horizons
Jin, R., Zhang, J., Wang, Y., Chen, Z., He, X., Zhang, X., Tan, Z., Kleer, C. G., Li, Y., Wang, D., et al. (2025) · Protein & Cell · doi:10.1093/procel/pwaf032 · Cited by 11
Fan, S., Du, H., Li, S., Xiao, G., Zhao, Y., He, S., Fan, G., & Zhu, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1491582 · Cited by 9
“Cardiac fi brosis is a common and key pathological process leading to heart failure in various heart diseases (Frangogiannis, 2021).”
Wang, Z., Niu, K., Liu, W., Wang, X., Yang, B., Li, T., Chen, Y., Jin, Y., Chen, Y., Lin, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202504552 · Cited by 9
Metadata
- Authors
- Frangogiannis, N. G.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Frangogiannis, Nikolaos G
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-02
- Volume
- 117
- Issue
- 6
- Pages
- 1450-1488
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- PMC
- PMC8152700
- OpenAlex
- W4210607007
- Cited by
- 1,229
- References
- 615
- Citations by year
- 2026: 265 · 2025: 319 · 2024: 273 · 2023: 210 · 2022: 130 · 2021: 32
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Cardiovascular Research (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH (R01 HL76246, R01 HL85440, R01 HL149407)
- U.S. Department of Defense (PR151134, PR151029, PR181464)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- myocardial fibrosis, myocardial fibroblasts, myofibroblasts, extracellular matrix deposition, TGF-beta, platelet-derived growth factor, cytokines, mechanoreceptors, integrins, pressure overload, myocardial infarction, heart failure, familial cardiomyopathy, diabetic cardiomyopathy, cardiac arrhythmias
- MeSH terms
- Antifibrotic Agents, Animals, Extracellular Matrix, Fibroblasts, Fibrosis, Humans, Cardiomyopathies, Myocytes, Cardiac, Mechanotransduction, Cellular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.